Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


3rd World Liver Congress

Dubai, UAE

Metin Basaranoglu

Metin Basaranoglu

Bezmialem Vakif University, Turkey

Title: Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list (Turkey)


Biography: Metin Basaranoglu


The aim of the study is to characterize Non-Alcoholic Fatty Liver Disease (NAFLD) presentation with esophageal varices. We carried out a retrospective cohort study on 258 patients with esophageal varices at a single tertiary referral center. These patients underwent diagnosis of several liver diseases, including, NAFLD associated cirrhosis, hepatitis B, hepatitis C, Wilson disease, autoimmune liver diseases, and others. Of the 258 patients, 39% of patients exhibited esophageal varices due to NAFLD-associated cirrhosis. Of the 38 (14.7%) patients developed hepatocellular carcinoma during follow-up, 52% were due to hepatitis B, 26% due to hepatitis C and 13.2% due to NAFLD. Of the 258 patients, 50.0% with NAFLD, 33.3% with hepatitis B, 26.3% with hepatitis C and 58.3% with other diseases were alive at the end of the 5-year period with a significant difference according to the Kaplan-Meier log Rank test P=0.040). Portal vein thrombosis was detected in 47.5% of patients with NAFLD, in 29% of patients with hepatitis B, in 17% of patients with hepatitis C and in 62% of patients with other related diseases ( P<0.0001). Our study showed a proportionally greater elevation in liver transplant candidacy in patients with NAFLD and portal vein thrombosis. Older patients were more prone to developing cirrhosis, hepatocellular carcinoma, and a high mortality rate. However, younger patients exhibited more portal vein thrombosis and gastric varices.